NO20084199L - Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom - Google Patents

Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom

Info

Publication number
NO20084199L
NO20084199L NO20084199A NO20084199A NO20084199L NO 20084199 L NO20084199 L NO 20084199L NO 20084199 A NO20084199 A NO 20084199A NO 20084199 A NO20084199 A NO 20084199A NO 20084199 L NO20084199 L NO 20084199L
Authority
NO
Norway
Prior art keywords
methods
formulations
inflammatory bowel
modified release
bowel disease
Prior art date
Application number
NO20084199A
Other languages
English (en)
Norwegian (no)
Inventor
Jackie Butler
John Devane
Original Assignee
Agi Therapeutics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Res Ltd filed Critical Agi Therapeutics Res Ltd
Publication of NO20084199L publication Critical patent/NO20084199L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/84—Hydrazones having doubly-bound carbon atoms of hydrazone groups being part of rings other than six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20084199A 2006-03-10 2008-10-07 Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom NO20084199L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/371,958 US7825106B2 (en) 2003-09-03 2006-03-10 Modified release formulations and methods of treating inflammatory bowel disease
PCT/IB2007/002029 WO2007119177A2 (fr) 2006-03-10 2007-03-07 Formulations à libération modifiée et méthodes de traitement de maladie intestinale inflammatoire

Publications (1)

Publication Number Publication Date
NO20084199L true NO20084199L (no) 2008-10-07

Family

ID=38609885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084199A NO20084199L (no) 2006-03-10 2008-10-07 Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom

Country Status (11)

Country Link
US (1) US7825106B2 (fr)
EP (1) EP1993517B1 (fr)
JP (1) JP5478898B2 (fr)
AU (1) AU2007237837A1 (fr)
CA (1) CA2643295A1 (fr)
ES (1) ES2739856T3 (fr)
IL (1) IL193776A0 (fr)
MX (1) MX2008011368A (fr)
NO (1) NO20084199L (fr)
WO (1) WO2007119177A2 (fr)
ZA (1) ZA200807304B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (fr) 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
PL2361620T3 (pl) 2004-02-06 2016-12-30 Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP2529729A1 (fr) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Préparations de balsalazide et leur fabrication
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
JP2011500553A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
BRPI0909818A2 (pt) * 2008-03-07 2015-10-06 Pfizer métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
EA022886B1 (ru) * 2008-10-03 2016-03-31 Др. Фальк Фарма Гмбх Способ поддержания ремиссии язвенного колита у пациентов
EP2468264A1 (fr) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Comprimé pharmaceutique oral pour la libération prolongée de mésalazine et son procédé de fabrication
EP2481411A1 (fr) * 2011-01-27 2012-08-01 Ratiopharm GmbH Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
US20120195966A1 (en) * 2011-01-27 2012-08-02 Frank Sievert Oral dosage form for modified release comprising a jak3 inhibitor
US20140178468A1 (en) * 2012-12-24 2014-06-26 Ranbaxy Laboratories Limited Multiparticulate extended-release composition of mesalamine
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CN105581993B (zh) * 2016-03-11 2018-06-29 常州欧法玛制药技术有限公司 一种阿司匹林渗透泵控释片及其制备方法
WO2018165404A1 (fr) * 2017-03-08 2018-09-13 Cinrx Pharma, Llc Formulations pharmaceutiques de phloroglucinol et de triméthylphloroglucinol
EP3662895A1 (fr) * 2018-12-07 2020-06-10 Tillotts Pharma AG Procédé de fabrication de noyaux de comprimés réduisant le 5-asa sans sucre

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (fr) 1980-03-20 1982-03-11
SE8002322L (sv) 1980-03-26 1981-09-27 Pharmacia Ab Medel for behandling av inflammatoriska tarmsjukdomar
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8303400D0 (sv) 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicylsyra och salt derav samt deras farmaceutiska beredning och anvendning
SE8303399D0 (sv) 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran
US4705515A (en) 1984-10-26 1987-11-10 Alza Corporation Dosage form for administering drug of the colon
US4627851A (en) 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4693895A (en) 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
FR2692484B1 (fr) 1992-06-22 1995-06-30 Gouchet Franck Nouvelle forme galenique de 4-asa a liberation controlee.
WO1995016451A1 (fr) 1992-06-22 1995-06-22 Franck Arno Gouchet Comprimes a liberation controlee de 4-asa
ATE195252T1 (de) 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
DE69528583T2 (de) 1994-04-22 2003-07-10 Yamanouchi Pharma Co Ltd Kolon-spezifisches arzneistofffreisetzungssystem
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5608048A (en) * 1995-06-05 1997-03-04 Bristol-Myers Squibb Company d4 T polymorphic Form 1 process
US6004581A (en) 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
EP1101490B1 (fr) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
KR100695562B1 (ko) 1998-09-28 2007-03-15 워너-램버트 캄파니 엘엘씨 Ｈｐｍｃ 캡슐을 이용한 장 및 결장에의 전달방법
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
JP2004507487A (ja) 2000-08-29 2004-03-11 メファ・アクチェンゲゼルシャフト 腸疾患治療薬
CA2359812C (fr) 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease

Also Published As

Publication number Publication date
ES2739856T3 (es) 2020-02-04
JP2009529524A (ja) 2009-08-20
EP1993517B1 (fr) 2019-05-08
ZA200807304B (en) 2009-07-29
WO2007119177A2 (fr) 2007-10-25
AU2007237837A1 (en) 2007-10-25
WO2007119177A3 (fr) 2008-06-26
CA2643295A1 (fr) 2007-10-25
US20060223787A1 (en) 2006-10-05
EP1993517A2 (fr) 2008-11-26
US7825106B2 (en) 2010-11-02
MX2008011368A (es) 2008-09-22
JP5478898B2 (ja) 2014-04-23
IL193776A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
WO2008085484A3 (fr) Procédé de traitement de l&#39;affection abdominale inflammatoire
TWI757228B (zh) 含有槲皮素配糖體之筋萎縮抑制劑
NO20061489L (no) Formuleringer og fremgangsmater for a behandle inflamatorisk tarmsykdom
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
WO2008079404A3 (fr) Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentés
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
WO2008028193A3 (fr) Formulations orales d&#39;analogues de cytidine administrées dans le côlon
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
MX348705B (es) Composiciones farmacéuticas y métodos de administración relacionados.
WO2011151722A3 (fr) Méthodes et compositions de traitement pharmaceutique par voie orale
HRP20180327T1 (hr) Sredstva za uporabu u slučaju intolerancije na fruktozu
MY145329A (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
WO2007023072A3 (fr) Utilisation d&#39;ambroxol pour traiter les infections a rhinovirus
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
WO2008002567A3 (fr) Méthodes de traitement d&#39;affections par administration à libération soutenue de dérivés de benzimidazole
WO2012044783A8 (fr) Procédé d&#39;obtention d&#39;une concentration de thymosine bêta 4 dans un patient humain
BRPI0507733A (pt) composição para a liberação de um agente hipnótico através da mucosa oral, e, método para tratar um distúrbio do sono em um paciente em necessidade deste
WO2019010301A8 (fr) Traitement de cardiopathies par inhibition de l&#39;action des protéines d&#39;ancrage aux protéines kinases a (makap) du muscle
WO2005056520A8 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
WO2008120617A1 (fr) Composition pharmaceutique pour empêcher la progression d&#39;une constriction intestinale associée à la maladie de crohn

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application